Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 243, Issue 12, 2005, Pages 1221-1227

  Renard, P ^a   Kovalski, J L ^b   Cochereau, I ^c   Jaulerry, S ^d   Williamson, W ^e   Elena, P P ^f   Lablache Combier, M ^g   Allaire, Catherine ^g   Siou Mermet, R ^g  

^a Institut Arthur Vernes   (France)

^b Military Teaching Hospital Clermont Tonnerre   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d Service de Biologie   (France)

^e François Mitterrand Hospital   (France)

^f Iris Pharma   (France)

^g BAUSCH AND LOMB   (United States)

Author keywords

Alginic acid; Beta blocker; Carteolol; Kinetics; Systemic delivery

Indexed keywords

CARTEOLOL; EYE DROPS; LONG ACTING DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INSTILLATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTRAOCULAR HYPERTENSION; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CARTEOLOL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; TREATMENT OUTCOME;

EID: 30344447681     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0024-5     Document Type: Article

References (19)

1. Demailly P, Allaire C, Trinquand C (2001) Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol 85:921-924 10.1136/bjo.85.8.921
2. Hasenfuß G, Schäefer-Korting M, Knauf H, Mutschler E, Just H (1985) Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol 29:461-465 10.1007/BF00613462
3. Ishii Y, Nakamura K, Matsuki S, Uemura N, Muraguchi R, Nakagawa M, Nakano S, Nakatsuka K (2002) Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity. J Clin Pharmacol 42:1020-1026 12211218
4. Konstas AGP, Maskaleris G, Gratsonidis S, Sardelli C (2000) Compliance and viewpoint of glaucoma patients in Greece. Royal college of ophthalmologists. Eye 14:752-756 11116698
5. Lesar TS (1987) Comparison of ophthalmic ß-blocking agents. Clin Pharm 6:451-463 2891463
6. Morita S, Iinuma M, Kido M, Sakuragi S, Kohri H, Nishino H (1977) Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new ß-adrenergic blocking agent. Drug Res 27:2380-2383
7. Negishi C, Kanai A, Nakajima A, Funahashi M, Kitazawa Y (1981) Ocular effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Jpn J Ophthalmol 25:464-476
8. Norell SE (1981)Monitoring compliance with pilocarpine therapy. Am J Ophthalmol 92:727-731 7304700
9. Note for guidance on the investigation of bio-availability and bio-equivalence. E.M.E.A. 2001
10. Ringham GL, Luther RR, Senello LT, Schambelan M, Humphreys MH (1985) A pharmacokinetic evaluation of carteolol in patients with impaired renal function. J Clin Pharmacol 25:468
11. Ringham GL, Senello LT, Jordan DC, Luther RR, Klepper MJ, Finley RA, Tolman KG (1987) Pharmacokinetics of carteolol in subjects of different ages. J Clin Pharmacol 27:715
12. Séchoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C (2000) A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm 207:109-116 10.1016/ S0378-5173(00)00539-1
13. Senello LT, Finley RA, Chu SY, Bunnell ST, Sonders RC, Ringham GL, Luther RR, Humphreys MH, Poon AH, Schambelan M (1987) The effect of impaired renal function on the multiple dose clinical pharmacokinetics of carteolol. Adv Ther 4:298-308
14. Schnarr K-D (1988) Vergleichende multizentrische Untersuchung von Carteolol-Augentropfen mit anderen Betablockern bei 768 Patienten unter Alltagsbedingungen. Klin Monatsbl Augenheilkd 192:167-172 2896266
15. Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Dunbar Hoskins H, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT (1991) A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefe Arch Clin Exp Ophthalmol 229:258-261 10.1007/BF00167880
16. Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL (1997) Efficacity of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol 124:498-505 9323940
17. Tissié G, Sébastian C, Elena PP, Driot JY, Trinquand C (2002) Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit. J Ocular Pharmacol Ther 18:65-73 10.1089/ 108076802317233225
18. Trinquand C, Romanet JP, Nordmann JP, Allaire C (2003) Efficacité et tolérance du carteolol 1% à libération prolongée une fois par jour. Etude randomisée en double insu. J Fr Ophtalmol 26:131-136 12660585
19. Zimmerman TJ (1993) Topical ophthalmic beta-blockers: A comparative review. J Ocul Pharmacol 9:373-384 7906296